

Edgar Filing: RIBAPHARM INC - Form 8-K

RIBAPHARM INC
Form 8-K
August 14, 2002

=====

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT: August 14, 2002
DATE OF EARLIEST EVENT REPORTED: August 14, 2002

RIBAPHARM INC.
(Exact name of registrant as specified in its charter)

DELAWARE	1-31294	95-4805665
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)

3300 HYLAND AVENUE
COSTA MESA, CALIFORNIA 92626

(Address of principal executive offices)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (714) 427-6236

=====

Item 9. Regulation FD Disclosure.

On August 14, 2002, Ribapharm Inc. ("Ribapharm") filed with the Securities and Exchange Commission its Quarterly Report on Form 10-Q for the period ended June 30, 2002. Accompanying such report were certifications by Ribapharm's Chief Executive Officer, Johnson Y.N. Lau, and Chief Financial Officer, Thomas Stankovich, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002. The text of each of these certifications follows:

Edgar Filing: RIBAPHARM INC - Form 8-K

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Ribapharm Inc. (the "Company") on Form 10-Q for the period ending June 30, 2002 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Johnson Y.N. Lau, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Johnson Y.N. Lau

Johnson Y.N. Lau
President and Chief Executive Officer
Dated: August 14, 2002

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Ribapharm Inc. (the "Company") on Form 10-Q for the period ending June 30, 2002 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Thomas Stankovich, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Thomas Stankovich

Thomas Stankovich
Senior Vice President and Chief Financial Officer
Dated: August 14, 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on behalf of the undersigned hereunto duly authorized.

Dated: August 14, 2002

Edgar Filing: RIBAPHARM INC - Form 8-K

RIBAPHARM INC.

By: /s/ Roger D. Loomis, Jr.

Name: Roger D. Loomis, Jr.

Title: Senior Vice President, General
Counsel and Secretary